HDL-C concentration is related to markers of absorption and of cholesterol synthesis: Study in subjects with low vs. high HDL-C

Clinica Chimica Acta

Volumn 412, Issue 1-2, 2011, Pages 176-180

  Nunes, V S ^a   Leanca C C ^a   Panzoldo, N B ^b   Parra, E ^b   Cazita, P M ^a   Nakandakare, E R ^a   de Faria, E C ^b   Quintao E C R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

sitosterol; Campesterol; Desmosterol; HDL C; Lathosterol; Lipoproteins

Indexed keywords

BIOLOGICAL MARKER; CAMPESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; DESMOSTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LATHOSTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SITOSTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTESTINE ABSORPTION; LIPID ABSORPTION; LIPOPROTEIN BLOOD LEVEL; MALE; MASS FRAGMENTOGRAPHY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ABSORPTION; ADULT; AGED; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; YOUNG ADULT;

EID: 78650517318     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.09.039     Document Type: Article

References (66)

1. Noto D., Cefalù A.B., Barraco G., et al. Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia. Pediatr Res 2010, 67:200-204.
2. van Himbergen T.M., Otokozawa S., Matthan N.R., et al. Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway. Arterioscler Thromb Vasc Biol 2010, 30:113-120.
3. García-Otín A.L., Cofán M., Junyent M., et al. Increased intestinal cholesterol absorption in autosomal dominant hypercholesterolemia and no mutations in the low-density lipoprotein receptor or apolipoprotein B genes. J Clin Endocrinol Metab 2007, 92:3667-3673.
4. Ketomäki A., Gylling H., Siimes M.A., Vuorio A., Miettinen T.A. Squalene and noncholesterol sterols in serum and lipoproteins of children with and without familial hypercholesterolemia. Pediatr Res 2003, 53:648-653.
5. Ooi E.M., Ng T.W., Chan D.C., Watts G.F. Plasma markers of cholesterol homeostasis in metabolic syndrome subjects with or without type-2 diabetes. Diab Res Clin Pract 2009, 85:310-316.
6. Gylling H., Laaksonen D.E., Atalay M., Hallikainen M., Niskanen L., Miettinen T.A. Markers of absorption and synthesis of cholesterol in men with type 1 diabetes. Diab Metab Res Rev 2007, 23:372-377.
7. Gylling H., Tuominen J.A., Koivisto V.A., Miettinen T.A. Cholesterol metabolism in type 1 diabetes. Diabetes 2004, 53:2217-2222.
8. Simonen P., Gylling H., Miettinen T.A. The validity of serum squalene and non-cholesterol sterols as surrogate markers of cholesterol synthesis and absorption in type 2 diabetes. Atherosclerosis 2008, 197:883-888.
9. Gylling H., Miettinen T.A. Inheritance of cholesterol metabolism of probands with high or low cholesterol absorption. J Lipid Res 2002, 43:1472-1476.
10. Assmann G., Cullen P., Kannenberg F., Schulte H. Relationship between phytosterol levels and components of the metabolic syndrome in the PROCAM study. Eur J Cardiovasc Prev Rehabil 2007, 14:208-214.
11. Nikkilä K., Miettinen T.A., Höckerstedt K.V., Isoniemi H. Sterol parameters as markers of liver function in primary biliary cirrhosis before and after liver transplantation. Transpl Int 2005, 18:221-225.
12. Lakoski S.G., Xu F., Vega G.L., et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab 2010, 95:800-809.
13. Matthan N.R., Resteghini N., Robertson M., et al. Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. J Lipid Res 2010, 51:202-209.
14. van Himbergen T.M., Matthan N.R., Resteghini N.A., et al. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res 2009, 50:730-739.
15. Miettinen T.A., Gylling H. Effect of statins on noncholesterol sterol levels: implications for use of plant stanols and sterols. Am J Cardiol 2005, 96:40D-46D.
16. Miettinen T.A., Gylling H. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur J Clin Invest 2003, 33:976-982.
17. Weingärtner O., Weingärtner N., Schaller B., et al. Alterations in cholesterol homeostasis are associated with coronary heart disease in patients with aortic stenosis. Coron Artery Dis 2009, 20:376-382.
18. Matthan N.R., Pencina M., LaRocque J.M., et al. Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD. J Lipid Res 2009, 50:1927-1935.
19. Miettinen T.A., Gylling H. Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high LDL cholesterol in a 4S subgroup. Atherosclerosis 2003, 168:343-349.
20. Gylling H., Rajaratnam R.A., Vartiainen E., Puska P., Miettinen T.A. Changes in serum level and metabolism of cholesterol with plant stanol esters in postmenopausal women with and without coronary artery disease. Menopause 2006, 13:286-293.
21. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
22. Kontush A., de Faria E.C., Chantepie S., Chapman M.J. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties. Arterioscler Thromb Vasc Biol 2004, 24:526-533.
23. Davidsson P., Hulthe J., Fagerberg B., Camejo G. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol 2010, 30:156-163.
24. Regieli J.J., Jukema J.W., Doevendans P.A., et al. Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J Am Coll Cardiol 2009, 54:1238-1245.
25. Schwartz C.C., Van den Broek J.M., Cooper P.S. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 2004, 45:1594-1607.
26. Rothblat G.H., Phillips M.C. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010, 21(3):229-238.
27. Scanu A.M., Edelstein C. HDL: bridging past and present with a look at the future. Faseb J 2008, 22:4044-4054.
28. Quintão E.C., Cazita P.M. Lipid transfer proteins: past, present and perspectives. Atherosclerosis 2010, 209:1-9.
29. Natarajan P., Ray K.K., Cannon C.P. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 2010, 55:1283-1299.
30. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diab Care 2004, 27:1487-1495.
31. Dobiasova M., Stribrna J., Pritchard P.H., Frohlich J.J. Cholesterol esterification rate in plasma depleted of very low and low density lipoproteins is controlled by the proportion of HDL2 and HDL3 subclasses: study in hypertensive and normal middle aged and septuagenarian men. J Lipid Res 1992, 33:1411-1418.
32. Lagrost L. Determination of the mass concentration and the activity of the plasma cholesteryl ester transfer protein (CETP). Meth Mol Biol 1998, 110:231-241.
33. McPherson R., Mann C.J., Tall A.R., et al. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler Thromb 1991, 11:797-804.
34. Miettinen T.A. Gas-liquid chromatographic determination of fecal neutral sterols using acapillary column. Clin Chim Acta 1982, 124:245-248.
35. Phillips K.M., Ruggio D.M., Bailey J.A. Precise quantitative determination of phytosterols, stanols, and cholesterol metabolites in human serum by capillary gas-liquid chromatography. J Chromatogr B Biomed Sci Appl 1999, 732:17-29.
36. Ahmida H.S., Bertucci P., Franzò L., et al. Simultaneous determination of plasmatic phytosterols and cholesterol precursors using gas chromatography-mass spectrometry (GC-MS) with selective ion monitoring (SIM). J Chromatogr B Anal Technol Biomed Life Sci 2006, 842:43-47.
37. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama 2002, 288:2709-2716.
38. Alexander C.M., Landsman P.B., Grundy S.M. Metabolic syndrome and hyperglycemia: congruence and divergence. Am J Cardiol 2006, 98:982-985.
39. Tang W., Ma Y., Jia L., Ioannou Y.A., Davies J.P., Yu L. Niemann-Pick C1-like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice. Arterioscler Thromb Vasc Biol 2008, 28:448-454.
40. Hallikainen M., Vidgren H., Agren J.J., Kiviniemi V., Miettinen T.A., Gylling H. Postprandial behavior of plasma squalene and non-cholesterol sterols in men with varying cholesterol absorption. Clin Chim Acta 2006, 374:63-68.
41. Drobnik W., Lindenthal B., Lieser B., et al. ATP-binding cassette transporter A1 (ABCA-1) affects total body sterol metabolism. Gastroenterology 2001, 120:1203-1211.
42. Groen A.K., Bloks V.W., Bandsma R.H., Ottenhoff R., Chimini G., Kuipers F. Hepatobiliary cholesterol transport is not impaired in ABCA-1-null mice lacking HDL. J Clin Invest 2001, 108:843-850.
43. Kosters A., Frijters R.J., Schaap F.G., et al. Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. J Hepatol 2003, 38:710-716.
44. Vasconcelos K.S., Sipahi A.M., Oliveira H.C., Castilho L.N., De Luccia N., Quintão E.C. Origin of intestinal lymph cholesterol in rats: contribution from luminal absorption, mucosal synthesis and filtration from plasma. Lymphology 1989, 22:4-12.
45. van der Velde A.E., Vrins C.L., van den Oever K., et al. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology 2007, 133:967-975.
46. Pertsemlidis D., Kirchman E.H., Ahrens E.H. Regulation of cholesterol metabolism in the dog. II. Effects of complete bile diversion and of cholesterol feeding on pool sizes of tissue cholesterol measured at autopsy. J Clin Invest 1973, 52:2368-2378.
47. Quintão E.C., Drewiacki A., Stechhaln K., de Faria E.C., Sipahi A.M. Origin of cholesterol transported in intestinal lymph: studies in patients with filarial chyluria. J Lipid Res 1979, 20:941-945.
48. Brunham L.R., Kruit J.K., Iqbal J., et al. Intestinal ABCA-1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006, 116:1052-1062.
49. Miettinen T.A. Cholesterol absorption, synthesis, and LDL metabolism in NIDDM. Diab Care 1997, 20:90-95.
50. Simonen P.P., Gylling H., Miettinen T.A. Body weight modulates cholesterol metabolism in non-insulin dependent type 2 diabetics. Obes Res 2002, 10:328-335.
51. Miettinen T.A., Gylling H., Tuominen J., Simonen P., Koivisto V. Low synthesis and high absorption of cholesterol characterize type 1 diabetes. Diab Care 2004, 27:53-58.
52. Tomkin G.H. The intestine as a regulator of cholesterol homeostasis in diabetes. Atheroscler Suppl 2008, 9:27-32.
53. O'Meara N.M., Devery R.A., Owens D., Collins P.B., Johnson A.H., Tomkin G.H. Cholesterol metabolism in alloxan-induced diabetic rabbits. Diabetes 1990, 39:626-633.
54. Miettinen T.A., Gylling H. Cholesterol absorption efficiency and sterol metabolism in obesity. Atherosclerosis 2000, 153:241-248.
55. Lee J.Y., Parks J.S. ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol 2005, 16:19-25.
56. Tang C., Oram J.F. The cell cholesterol exporter ABCA-1 as a protector from cardiovascular disease and diabetes. Biochim Biophys Acta 2009, 1791:563-572.
57. Harchaoui K.E., Franssen R., Hovingh G.K., et al. Reduced fecal sterol excretion in subjects with familial hypoalphalipoproteinemia. Atherosclerosis 2009, 207:614-616.
58. Smahelová A., Hyspler R., Haas T. Relation of cholesterol metabolism and non-cholesterol sterols to insulin resistance. Physiol Res 2007, 56:749-755.
59. Simonen P.P., Gylling H., Miettinen T.A. The distribution of squalene and non-cholesterol sterols in lipoproteins in type 2 diabetes. Atherosclerosis 2007, 194:222-229.
60. Quintão E., Grundy S.M., Ahrens E.H. Effects of dietary cholesterol on the regulation of total body cholesterol in man. J Lipid Res 1971, 12:233-247.
61. Weingärtner O., Lütjohann D., Böhm M., Laufs U. Relationship between cholesterol synthesis and intestinal absorption is associated with cardiovascular risk. Atherosclerosis 2010, 210:362-365.
62. Miettinen T.A., Kesäniemi Y.A. Cholesterol absorption: regulation of cholesterol synthesis and elimination and within-population variations of serum cholesterol levels. Am J Clin Nutr 1989, 49:629-635.
63. Beher W.T., Gabbard A., Norum R.A., Stradnieks S. Effect of blood high density lipoprotein cholesterol concentration on fecal steroid excretion in humans. Life Sci 1983, 32:2933-2937.
64. Gylling H., Miettinen T.A. Non-cholesterol sterols, absorption and synthesis of cholesterol and apolipoprotein A-I kinetics in a Finnish lecithin-cholesterol acyltransferase deficient family. Atherosclerosis 1992, 95:25-33.
65. Drew B.G., Duffy S.J., Formosa M.F., et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009, 119:2103-2111.
66. Brunham L.R., Kruit J.K., Pape T.D., et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007, 13:340-347.